{"schema_version":"secwatch.filing_event.v1","accession":"0001662774-24-000010","form_type":"8-K","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2024-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.150945+00:00","generated_at":"2026-05-30T00:57:32.068095+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Quince Therapeutics Q3 net loss $5.5M; Phase 3 NEAT enrollment at 32 patients","bullets":["Phase 3 NEAT trial enrolled 32 patients; on track to complete enrollment in Q2 2025 with topline results in Q4 2025.","Cash, equivalents, and short-term investments of $47.8M; runway expected into 2026 through topline results.","Net loss of $5.5M ($0.13 per share) for Q3 2024; R&D expenses $4.9M, G&A expenses $3.6M.","Plans to initiate a Phase 2 Duchenne muscular dystrophy study in 2025.","Identified 11 potential new rare disease indications for EryDex beyond A-T and DMD."],"urls":{"canonical":"https://secwatch.observer/filing/0001662774-24-000010","json":"https://secwatch.observer/filing/0001662774-24-000010.json","markdown":"https://secwatch.observer/filing/0001662774-24-000010.md","text":"https://secwatch.observer/filing/0001662774-24-000010.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/0001662774-24-000010-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000166277424000010/qncx-20241113.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:57:32.068095+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}